The sensitivity of VCA‐IgA is not high enough (about 60%‐70%) to meet the needs for clinic.34 Similarly, the detection rate of VCA‐IgA in our research was only 68.2% (Table 1), with about 30% of patients missing diagnosis, probably due to the immunocompromise with a cancer burden.37 In view of this, a protein in sera is not directly limited by immune status, could be a potential solution. Here, CD79A is linked to cancer.